Microbot Medical’s FDA-Cleared LIBERTY System Wins Startup Award After Seven-State Adoption
MBOT•Microbot Medical’s single-use, FDA-cleared LIBERTY robotic system for peripheral endovascular procedures has been installed at academic centers across seven US states since its April market debut. It won the Innovative Start-Up Award for offering precise vascular navigation, efficiency gains and reduced radiation exposure and operator strain.
1. Innovative Start-Up Award
Microbot Medical’s LIBERTY Endovascular Robotic System received the Innovative Start-Up Award, recognizing its groundbreaking technology and commercial progress within the surgical robotics industry.
2. Rapid Commercial Adoption
Following its full market release in early April, the LIBERTY system has been installed at leading academic centers in seven states, including New York, Pennsylvania, Florida, Georgia, Massachusetts, Michigan and North Carolina.
3. System Design and Advantages
As the only FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures, LIBERTY delivers precise vascular navigation, enhances procedural efficiency and reduces both operator radiation exposure and physical strain.
4. Strategic Outlook
Microbot Medical is focused on expanding system adoption through targeted commercial strategies, advancing product innovation and broadening access to its robotically assisted endovascular solutions.
